Cargando…

Dual Delivery of Tetramethylpyrazine and miR-194-5p Using Soft Mesoporous Organosilica Nanoparticles for Acute Lung Injury Therapy

BACKGROUND: The respiratory system is intensely damaged by acute lung injury (ALI). The anti-inflammatory effects of tetramethylpyrazine (TMP) against ALI have been confirmed, but it exhibits a short half-life. miR-194-5p could directly target Rac1, but the internalization rate of miRNA cells was lo...

Descripción completa

Detalles Bibliográficos
Autores principales: Min, Simin, Tao, Weiting, Miao, Yuchen, Li, Yan, Wu, Tianyu, He, Xiaoyu, Zhang, Yijing, Liu, Bangye, Meng, Zixin, Han, Ke, Liu, Saisai, Li, Li, Chen, Jie, Zhao, Shidi, Zhang, Junjie, Zhang, Xiaonan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10640848/
https://www.ncbi.nlm.nih.gov/pubmed/38026537
http://dx.doi.org/10.2147/IJN.S420802
_version_ 1785133842160418816
author Min, Simin
Tao, Weiting
Miao, Yuchen
Li, Yan
Wu, Tianyu
He, Xiaoyu
Zhang, Yijing
Liu, Bangye
Meng, Zixin
Han, Ke
Liu, Saisai
Li, Li
Chen, Jie
Zhao, Shidi
Zhang, Junjie
Zhang, Xiaonan
author_facet Min, Simin
Tao, Weiting
Miao, Yuchen
Li, Yan
Wu, Tianyu
He, Xiaoyu
Zhang, Yijing
Liu, Bangye
Meng, Zixin
Han, Ke
Liu, Saisai
Li, Li
Chen, Jie
Zhao, Shidi
Zhang, Junjie
Zhang, Xiaonan
author_sort Min, Simin
collection PubMed
description BACKGROUND: The respiratory system is intensely damaged by acute lung injury (ALI). The anti-inflammatory effects of tetramethylpyrazine (TMP) against ALI have been confirmed, but it exhibits a short half-life. miR-194-5p could directly target Rac1, but the internalization rate of miRNA cells was low. PURPOSE: To explore the potential of the soft mesoporous organic silica nanoplatform (NPs) as carriers for delivery of TMP and miR-194-5p through the tail vein. METHODS: NPs@TMP and NPs@PEI@miR-194-5p were added to the HUVEC cell-lines, in vitro, to observe the cell uptake and cytotoxic effects. In vivo experiments were conducted by injecting fluorescently labeled NPs through the tail vein and tracking distribution. Therapeutic and toxic side-effects were analyzed systemically. RESULTS: In vitro study exhibited that NPs have no toxic effect on HUVECs within the experimental parameters and have excellent cellular uptake. The IVIS Spectrum Imaging System shows that NPs accumulate mainly in the lungs. NPs@TMP treatment can improved oxidative stress and inflammation levels in ALI mice and inhibited the TLR4/NLRP3/caspase 1 pathway. NPs@PEI@miR-194-5p can inhibit the Rac1/ZO-1/occludin pathway and improved endothelial cell permeability in ALI mice. The co-treatment of NPs@TMP and NPs@PEI@miR-194-5p can significantly improved the survival rates of the mice, reduced pulmonary capillary permeability and improved pathological injury in ALI mice. INNOVATION: This study combined traditional Chinese medicine, bioinformatics, cellular molecular biology and nanobiomedicine to study the pathogenesis and treatment of ALI. The rate of cellular internalization was improved by changing the shape and hardness of nanoparticles. NPs@TMP and NPs@PEI@miR-194-5p combined application can significantly improve the survival condition and pathological injury of mice. CONCLUSION: NPs loaded with TMP and miR-194-5p showed a greater therapeutic effect in ALI mice.
format Online
Article
Text
id pubmed-10640848
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-106408482023-11-08 Dual Delivery of Tetramethylpyrazine and miR-194-5p Using Soft Mesoporous Organosilica Nanoparticles for Acute Lung Injury Therapy Min, Simin Tao, Weiting Miao, Yuchen Li, Yan Wu, Tianyu He, Xiaoyu Zhang, Yijing Liu, Bangye Meng, Zixin Han, Ke Liu, Saisai Li, Li Chen, Jie Zhao, Shidi Zhang, Junjie Zhang, Xiaonan Int J Nanomedicine Original Research BACKGROUND: The respiratory system is intensely damaged by acute lung injury (ALI). The anti-inflammatory effects of tetramethylpyrazine (TMP) against ALI have been confirmed, but it exhibits a short half-life. miR-194-5p could directly target Rac1, but the internalization rate of miRNA cells was low. PURPOSE: To explore the potential of the soft mesoporous organic silica nanoplatform (NPs) as carriers for delivery of TMP and miR-194-5p through the tail vein. METHODS: NPs@TMP and NPs@PEI@miR-194-5p were added to the HUVEC cell-lines, in vitro, to observe the cell uptake and cytotoxic effects. In vivo experiments were conducted by injecting fluorescently labeled NPs through the tail vein and tracking distribution. Therapeutic and toxic side-effects were analyzed systemically. RESULTS: In vitro study exhibited that NPs have no toxic effect on HUVECs within the experimental parameters and have excellent cellular uptake. The IVIS Spectrum Imaging System shows that NPs accumulate mainly in the lungs. NPs@TMP treatment can improved oxidative stress and inflammation levels in ALI mice and inhibited the TLR4/NLRP3/caspase 1 pathway. NPs@PEI@miR-194-5p can inhibit the Rac1/ZO-1/occludin pathway and improved endothelial cell permeability in ALI mice. The co-treatment of NPs@TMP and NPs@PEI@miR-194-5p can significantly improved the survival rates of the mice, reduced pulmonary capillary permeability and improved pathological injury in ALI mice. INNOVATION: This study combined traditional Chinese medicine, bioinformatics, cellular molecular biology and nanobiomedicine to study the pathogenesis and treatment of ALI. The rate of cellular internalization was improved by changing the shape and hardness of nanoparticles. NPs@TMP and NPs@PEI@miR-194-5p combined application can significantly improve the survival condition and pathological injury of mice. CONCLUSION: NPs loaded with TMP and miR-194-5p showed a greater therapeutic effect in ALI mice. Dove 2023-11-08 /pmc/articles/PMC10640848/ /pubmed/38026537 http://dx.doi.org/10.2147/IJN.S420802 Text en © 2023 Min et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Min, Simin
Tao, Weiting
Miao, Yuchen
Li, Yan
Wu, Tianyu
He, Xiaoyu
Zhang, Yijing
Liu, Bangye
Meng, Zixin
Han, Ke
Liu, Saisai
Li, Li
Chen, Jie
Zhao, Shidi
Zhang, Junjie
Zhang, Xiaonan
Dual Delivery of Tetramethylpyrazine and miR-194-5p Using Soft Mesoporous Organosilica Nanoparticles for Acute Lung Injury Therapy
title Dual Delivery of Tetramethylpyrazine and miR-194-5p Using Soft Mesoporous Organosilica Nanoparticles for Acute Lung Injury Therapy
title_full Dual Delivery of Tetramethylpyrazine and miR-194-5p Using Soft Mesoporous Organosilica Nanoparticles for Acute Lung Injury Therapy
title_fullStr Dual Delivery of Tetramethylpyrazine and miR-194-5p Using Soft Mesoporous Organosilica Nanoparticles for Acute Lung Injury Therapy
title_full_unstemmed Dual Delivery of Tetramethylpyrazine and miR-194-5p Using Soft Mesoporous Organosilica Nanoparticles for Acute Lung Injury Therapy
title_short Dual Delivery of Tetramethylpyrazine and miR-194-5p Using Soft Mesoporous Organosilica Nanoparticles for Acute Lung Injury Therapy
title_sort dual delivery of tetramethylpyrazine and mir-194-5p using soft mesoporous organosilica nanoparticles for acute lung injury therapy
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10640848/
https://www.ncbi.nlm.nih.gov/pubmed/38026537
http://dx.doi.org/10.2147/IJN.S420802
work_keys_str_mv AT minsimin dualdeliveryoftetramethylpyrazineandmir1945pusingsoftmesoporousorganosilicananoparticlesforacutelunginjurytherapy
AT taoweiting dualdeliveryoftetramethylpyrazineandmir1945pusingsoftmesoporousorganosilicananoparticlesforacutelunginjurytherapy
AT miaoyuchen dualdeliveryoftetramethylpyrazineandmir1945pusingsoftmesoporousorganosilicananoparticlesforacutelunginjurytherapy
AT liyan dualdeliveryoftetramethylpyrazineandmir1945pusingsoftmesoporousorganosilicananoparticlesforacutelunginjurytherapy
AT wutianyu dualdeliveryoftetramethylpyrazineandmir1945pusingsoftmesoporousorganosilicananoparticlesforacutelunginjurytherapy
AT hexiaoyu dualdeliveryoftetramethylpyrazineandmir1945pusingsoftmesoporousorganosilicananoparticlesforacutelunginjurytherapy
AT zhangyijing dualdeliveryoftetramethylpyrazineandmir1945pusingsoftmesoporousorganosilicananoparticlesforacutelunginjurytherapy
AT liubangye dualdeliveryoftetramethylpyrazineandmir1945pusingsoftmesoporousorganosilicananoparticlesforacutelunginjurytherapy
AT mengzixin dualdeliveryoftetramethylpyrazineandmir1945pusingsoftmesoporousorganosilicananoparticlesforacutelunginjurytherapy
AT hanke dualdeliveryoftetramethylpyrazineandmir1945pusingsoftmesoporousorganosilicananoparticlesforacutelunginjurytherapy
AT liusaisai dualdeliveryoftetramethylpyrazineandmir1945pusingsoftmesoporousorganosilicananoparticlesforacutelunginjurytherapy
AT lili dualdeliveryoftetramethylpyrazineandmir1945pusingsoftmesoporousorganosilicananoparticlesforacutelunginjurytherapy
AT chenjie dualdeliveryoftetramethylpyrazineandmir1945pusingsoftmesoporousorganosilicananoparticlesforacutelunginjurytherapy
AT zhaoshidi dualdeliveryoftetramethylpyrazineandmir1945pusingsoftmesoporousorganosilicananoparticlesforacutelunginjurytherapy
AT zhangjunjie dualdeliveryoftetramethylpyrazineandmir1945pusingsoftmesoporousorganosilicananoparticlesforacutelunginjurytherapy
AT zhangxiaonan dualdeliveryoftetramethylpyrazineandmir1945pusingsoftmesoporousorganosilicananoparticlesforacutelunginjurytherapy